The fusion biopsy market is expected to be worth around $803.50 million by 2035, driven by increasing adoption of precision prostate cancer diagnostics. This growth is reported by some outlets, which provide a specific value for the market size. Meanwhile, a separate market, the global concierge medicine market, is also expected to experience significant growth, reaching a value of $41.37 billion by 2035, though its connection to the fusion biopsy market is unclear.